BioAtla Investor Presentation Deck

CAB-CTLA-4 (BA3071) Effectively Reduces Clinically Relevant GI Toxicity in NHP bicatla * Vehicle Control Nivo + IPI 20mg/kg + 15mg/kg Study date 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Cvno # wwwwwwwwww Nivo + CAB-BA3071 20mg/kg + 15mg/kg #1 #2 #3 #4 #5 #1 #1 or #2 #2 #3 #4 #5 #1 #2 #3 #4 #5 A GI Symptoms Liquid feces Non-formed feces Other Gl symptoms Nivo: 20mg/kg QW (~14.6mg/kg human dose) + Ipi or BA3071: 15mg/kg QW (~11mg/kg human dose) Once weekly for four weeks exposure to Nivo + Ipi or BA3071 NHP Nonhuman primates *Chang et al., PNAS 118 (9): 1-10, 2021 BA3071 significantly reduces Gl toxicity relative to ipilimumab analog in combination with nivo BioAtla| Overview 11

View entire presentation